Sweden's Xintela Q2 loss narrows as income rises, costs drop
28/08/2026 09:48
((This story was generated using AI and automation, please see disclaimerhttps://bit.ly/rtrsnai )) Overview * Sweden biopharma firm's Q2 income rose, loss before tax narrowed on higher sales, lower costs * Loss per share for Q2 improved to SEK 0.01 from SEK 0.02 * Company secured SEK 30 mln convertible loan to accelerate XSTEM® development and repay debt Outlook * Company did not provide specific guidance for future quarters or full-year results Result Drivers * EQGEN PROJECT - Co said increased net sales in Q2 were driven by work on the EQGen project * LOWER COSTS - Co said reduced costs contributed to improved pre-tax result in Q2 Company press release:ID:nMFN8tYb4L Key Details Metric Beat/Mis Actual Consensu s s Estimate Q2 Loss SEK 0.01 Per Share Reuters Recommended Reads * Aug 26 - Sweden's Modus Therapeutics narrows Q2 net loss, extends financing * Aug 26 - Sweden's Cereno Scientific Q2 net loss widens, hurt by clinical development costs * Aug 27 - Sweden's BioInvent Q2 net sales drop, loss widens For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)